Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in:

Open Access 01-12-2017 | Research

Anti-Candida activity of antimicrobial impregnated central venous catheters

Authors: L. Cobrado, A. Silva-Dias, M. M. Azevedo, A. Rodrigues

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2017

Login to get access

Abstract

Background

Whenever the rate of central line-associated bloodstream infections (CLABSIs) remains high even after the implementation of preventive strategies, the use of chlorhexidine/silver sulfadiazine (CSS) or minocycline/rifampin (MR)-impregnated central venous catheters (CVCs) is currently recommended. Nevertheless, the efficacy of such CVCs against Candida albicans and other emerging non-albicans spp. has been insufficiently studied. This study aims to compare the activity of CSS and MR-impregnated CVCs against the yeasts most frequently isolated from CLABSIs.

Methods

For biofilm formation assays, type strains and clinical isolates of C. albicans, C. glabrata and C. parapsilosis sensu stricto were used. Segments of standard polyurethane, MR and second-generation CSS-CVCs were tested. The biofilm metabolic activity was measured by a semi-quantitative XTT reduction assay.

Results

CSS catheter segments significantly reduced the biofilm metabolic activity by all tested Candida spp., with inhibition ranging from 60% to 100%. The MR catheter segments promoted C. albicans and C. parapsilosis biofilm formation and exhibited an inconspicuous effect against C. glabrata.

Conclusions

Among the recommended antimicrobial CVCs, CSS-CVCs proved to be superior in the inhibition of biofilm formation by the most frequent yeasts causing CLABSIs. Data from this in vitro study may suggest that patients at high risk for invasive candidosis could benefit from the use of CSS-CVCs.
Literature
1.
2.
3.
4.
Magill SS, Edwards JR, Fridkin SK. Emerging infections program healthcare-associated I, antimicrobial use prevalence survey T. Survey of health care-associated infections. N Engl J Med. 2014;370:2542–3.CrossRefPubMed
5.
Raad I, Reitzel R, Jiang Y, Chemaly RF, Dvorak T, Hachem R. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria. J Antimicrob Chemother. 2008;62:746–50.CrossRefPubMed
6.
Wenzel RP. Nosocomial Candidemia - risk-factors and attributable mortality. Clin Infect Dis. 1995;20:1531–4.CrossRefPubMed
7.
8.
Ingham CJ, Boonstra S, Levels S, de Lange M, Meis JF, Schneeberger PM. Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide. Plos One. 2012;7:e33818.CrossRefPubMedPubMedCentral
9.
10.
Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol. 2007;45:3522–8.CrossRefPubMedPubMedCentral
11.
Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and Nosocomial isolates in the SENTRY antimicrobial surveillance program, 2008-2009. Antimicrob Agents Ch. 2011;55:561–6.CrossRef
12.
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349–53.CrossRefPubMed
13.
14.
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of Candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.CrossRefPubMed
15.
Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Giannini MJSM. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62:10–24.CrossRefPubMed
16.
Pereira GH, Muller PR, Szeszs MW, Levin AS, Melhem MSC. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. Albicans Candida species. Med Mycol. 2010;48:839–42.CrossRefPubMed
17.
O'Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52:e162–93.CrossRefPubMedPubMedCentral
18.
19.
20.
Schierholz JM, Fleck C, Beuth J, Pulverer G. The antimicrobial efficacy of a new central venous catheter with long-term broad-spectrum activity. J Antimicrob Chemother. 2000;46:45–50.CrossRefPubMed
21.
AFE R, Guttler K, Konig DP, Yucel N, Korenkov M, Schierholz JM. Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter. J Hosp Infect. 2003;53:129–35.CrossRef
22.
Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware RA. Prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med. 2006;34:668–75.CrossRefPubMed
23.
Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ, Metzler MH, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters - a randomized controlled trial. Ann Surg. 2005;242:193–200.CrossRefPubMedPubMedCentral
24.
Leon C, Ruiz-Santana S, Rello J, de la Torre MV, Valles J, Alvarez-Lerma F, et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med. 2004;30:1891–9.CrossRefPubMed
25.
Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008;3:1494–500.CrossRefPubMedPubMedCentral
26.
Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132:391–402.CrossRefPubMed
27.
Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection - a meta-analysis. Jama-J Am Med Assoc. 1999;281:261–7.CrossRef
28.
Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intens Care Med. 2004;30:837–43.CrossRef
29.
Ostendorf T, Meinhold A, Harter C, Salwender H, Egerer G, Geiss HK, et al. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients - a double-blind, randomised, prospective, controlled trial. Support Care Cancer. 2005;13:993–1000.CrossRefPubMed
30.
Rupp ME, Lisco SJ, Lipsett PA, Ped TM, Keating K, Civetta JM, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter - related infections - a randomized, controlled trial. Ann Intern Med. 2005;143:570–80.CrossRefPubMed
31.
Oda T, Hamasaki J, Kanda N, Mikami K. Anaphylactic shock induced by an antiseptic-coated central nervous catheter. Anesthesiology. 1997;87:1242–4.CrossRefPubMed
32.
Stephens R, Mythen M, Kallis P, Davies DWL, Egner W, Rickards A. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Brit J Anaesth. 2001;87:306–8.CrossRefPubMed
33.
Terazawa E, Shimonaka H, Nagase K, Masue T, Dohi S. Severe anaphylactic reaction due to a chlorhexidine-impregnated central venous catheter. Anesthesiology. 1998;89:1296–8.CrossRefPubMed
34.
Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter - a randomized, controlled trial. Ann Intern Med. 1997;127:257–66.CrossRefPubMed
35.
Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al. A comparison of two antimicrobial-impregnated central venous catheters. New Engl J Med. 1999;340:1–8.CrossRefPubMed
36.
Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173:418–24.CrossRefPubMed
37.
Gaonkar TA, Modak SM. Comparison of microbial adherence to antiseptic and antibiotic central venous catheters using a novel agar subcutaneous infection model. J Antimicrob Chemother. 2003;52:389–96.CrossRefPubMed
38.
Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemoth. 2007;59:359–69.CrossRef
39.
Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemoth. 2001;47:589–98.CrossRef
40.
Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Cont Hosp Ep. 2001;22:640–6.CrossRef
41.
Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008;72:157–65.CrossRefPubMed
42.
Chandra J, Mukherjee PK, Ghannoum MA. Vitro growth and analysis of Candida biofilms. Nat Protoc. 2008;3:1909–24.CrossRefPubMed
43.
Hanna H, Bahna P, Reitzel R, Dvorak T, Chaiban G, Hachem R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Ch. 2006;50:3283–8.CrossRef
44.
Novikov A, Lam MY, Mermel LA, Casey AL, Elliott TS, Nightingale P. Impact of catheter antimicrobial coating on species-specific risk of catheter colonization: a meta-analysis. Antimicrob Resist In. 2012;1:40.CrossRef
45.
Raad I, Mohamed JA, Reitzel RA, Jiang Y, Raad S, Al Shuaibi M, et al. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. Antimicrob Agents Chemother. 2012;56:935–41.CrossRefPubMedPubMedCentral
46.
Yucel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. J Antimicrob Chemoth. 2004;54:1109–15.CrossRef
47.
Lorente L, Lecuona M, Ramos MJ, Jimenez A, Mora ML, Sierra A. The use of rifampicin-miconazole-impregnated catheters reduces the incidence of femoral and jugular catheter-related bacteremia. Clin Infect Dis. 2008;47:1171–5.CrossRefPubMed
Metadata
Title
Anti-Candida activity of antimicrobial impregnated central venous catheters
Authors
L. Cobrado
A. Silva-Dias
M. M. Azevedo
A. Rodrigues
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2017
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-017-0269-x

Other articles of this Issue 1/2017

Emerging antimicrobial resistance in early and late-onset neonatal sepsis

  • Open Access
  • Research

Relationship between hospital ward design and healthcare associated infection rates: what does the evidence really tell us? Comment on Stiller et al. 2016

  • Open Access
  • Letter to the Editor

Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a case–control study

  • Open Access
  • Research

The incidence of MRSA infections in the United States: is a more comprehensive tracking system needed?

  • Open Access
  • Short report

Detection of diverse genotypes of Methicillin-resistant Staphylococcus aureus from hospital personnel and the environment in Armenia

  • Open Access
  • Research

Non-prescribed antimicrobial use and associated factors among customers in drug retail outlet in Central Zone of Tigray, northern Ethiopia: a cross-sectional study

  • Open Access
  • Research

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits